News
AGRX
1.440
+0.70%
0.010
Weekly Report: what happened at AGRX last week (0715-0719)?
Weekly Report · 1d ago
Weekly Report: what happened at AGRX last week (0708-0712)?
Weekly Report · 07/15 09:51
Weekly Report: what happened at AGRX last week (0701-0705)?
Weekly Report · 07/08 09:51
Weekly Report: what happened at AGRX last week (0624-0628)?
Weekly Report · 07/01 09:52
AGILE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Agile Therapeutics, Inc. - AGRX
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Agile Therapeutics, Inc. To Insud Pharma, S.L. Under the terms of the proposed transaction, shareholders will receive $1.52 in cash for each share. KSF is seeking to determine whether the consideration undervalues the Company.
Barchart · 06/28 17:14
Agile Therapeutics Merges with Insud Pharma Subsidiary
TipRanks · 06/26 12:32
Agile Therapeutics to be acquired by Spain-based Insud for an enterprise value of ~$45M
Healthcare M&A Agile Therapeutics to be acquired by Spain-based Insud for an enterprise value of ~$45M. The transaction is priced at $1.52 per share in cash. Insud's U.S. Subsidiary, Exeltis Project, will merge with Agile.
Seeking Alpha · 06/26 12:12
Press Release: Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Dow Jones · 06/26 11:48
Press Release: Agile Therapeutics Inc. Announces -2-
Dow Jones · 06/26 11:48
AGILE THERAPEUTICS INC - INSUD TO PROVIDE AGILE WITH UP TO $8 MILLION LINE OF CREDIT
Reuters · 06/26 11:45
AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC is investigating whether the sale of Agile Therapeutics, Inc. To Insud Pharma, S.L. For $1.52 per share in cash is fair to Agile shareholders. The investigation concerns whether Agile and its board of directors violated the federal securities laws. Halper sadeh is an investor rights law firm.
Barchart · 06/26 09:26
Weekly Report: what happened at AGRX last week (0617-0621)?
Weekly Report · 06/24 09:54
Weekly Report: what happened at AGRX last week (0610-0614)?
Weekly Report · 06/17 09:51
Weekly Report: what happened at AGRX last week (0603-0607)?
Weekly Report · 06/10 09:52
Weekly Report: what happened at AGRX last week (0527-0531)?
Weekly Report · 06/03 09:53
Weekly Report: what happened at AGRX last week (0520-0524)?
Weekly Report · 05/27 09:55
Weekly Report: what happened at AGRX last week (0513-0517)?
Weekly Report · 05/20 09:52
AGRX Stock Earnings: Agile Therapeutics Misses EPS, Beats Revenue for Q1 2024
Agile Therapeutics reported earnings per share of -63 cents for the first quarter of 2024. The company reported revenue of $ million. This was better than the analyst estimate for revenue of $ million. Agile TherAPEutics just reported results.
Investorplace · 05/16 02:54
Agile Therapeutics, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024
Press release · 05/15 22:48
Agile Therapeutics Non-GAAP EPS of -$0.63, revenue of $5.7M
Seeking Alpha · 05/15 20:58
More
Webull provides a variety of real-time AGRX stock news. You can receive the latest news about Agile Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AGRX
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.